Search

Your search keyword '"Benyamini, Noam"' showing total 234 results
Start Over Author "Benyamini, Noam"
234 results on '"Benyamini, Noam"'

1. Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis

Author

Avivi, Irit, Perry, Chava, Segman, Yafit, Amit, Odelia, Bar-On, Yaeli, Katz, Ofrat Beyer, Gold, Ronit, Ribakovsky, Elena, Avigdor, Abraham, Vainstein, Vladimir, Goldschmidt, Neta, Ringelstein-Harlev, Shimrit, Horowitz, Netanel A., Gutwein, Odit, Gurion, Ronit, Itchaki, Gilad, Abadi, Uri, Nemets, Anatoly, Sofer, Orit, Vezker, Miri, Tadmor, Tamar, Dally, Najib, Filanovsky, Kalman, Leiba, Merav, Sarid, Nadav, Benyamini, Noam, Luttwak, Efrat, Herishanu, Yair, and Ram, Ron

Published
2022
Full Text
View/download PDF

2. Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study

Author

Ram, Ron, Hagin, David, Kikozashvilli, Nino, Freund, Tal, Amit, Odelia, Bar-On, Yael, Beyar-Katz, Ofrat, Shefer, Gabi, Moshiashvili, Miguel Morales, Karni, Chen, Gold, Ronit, Kay, Sigi, Glait-Santar, Chen, Eshel, Rinat, Perry, Chava, Avivi, Irit, Apel, Arie, Benyamini, Noam, Shasha, David, and Ben-Ami, Ronen

Published
2021
Full Text
View/download PDF

4. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

Author

Nicol, Andrew, Grigoriadis, George, Catalano, John, LeBlanc, Richard, Elemary, Mohamed, Bahlis, Nizar, Facon, Thierry, Karlin, Lionel, Ribrag, Vincent, Attal, Michel, Goldschmidt, Hartmut, Engelhardt, Monika, Weisel, Katja, Mackensen, Andreas, Nagler, Arnon, Ben Yehuda, Dina, Avivi, Irit, Benyamini, Noam, Magen-Nativ, Hila, Palumbo, Antonio, Cavo, Michele, Tobinai, Kensei, Iida, Shinsuke, Chou, Takaai, Suzuki, Kenshi, Kosugi, Hiroshi, Taniwaki, Masafumi, Sunami, Kazutaka, Matsumoto, Morio, Ando, Kiyoshi, Ganly, Peter, Blacklock, Hilary, Simpson, David, George, Anupkumar, Schjesvold, Fredrik, Gjertsen, Bjorn, Lahuerta, Juan, Blade, Joan, Oriol Rocafiguera, Albert, Mateos, Maria, Rodriguez-Otero, Paula, Larson, Sarah, Atanackovic, Djordje, Devarakonda, Srinivas, Bitran, Jacob, Zonder, Jeffrey, Morganstein, Neil, Hay, Mohammad, Chanan-Khan, Asher, Saylors, Gene, Kio, Ebenezer, Oliff, Ira, Kirkel, Dean, Shtivelband, Mikhail, Yuen, Carrie, Yee, Andrew, Shah, Jatin, Htut, Myo, Raza, Shahzad, Chhabra, Saurabh, Stiff, Patrick, Hari, Parameswaran, Bank, Bruce, Malek, Ehsan, Gasparetto, Cristina, Faroun, Ycaoub, Sherbenou, Daniel, Kreisle, William, Singhal, Seema, Rosenblatt, Jacalyn, Usmani, Saad, Lee, Wes, Safah, Hana, Lutzky, Jose, Suh, Jason, Pan, Dorothy, Baron, Ari, Manges, Robert, Steis, Ronald, Oliveira, Moacyr, Moreb, Jan, Callander, Natalie, Anz, Bertrand, Raptis, Anastasios, Stampleman, Laura, Melear, Jason, Boyd, Thomas, Garbo, Lawrence, Klein, Leonard, Shao, Spencer, Lyons, Roger, McIntyre, Kristi, Tarantolo, Stefano, Yasenchak, Christopher, Yimer, Habte, Mateos, Maria-Victoria, Oriol, Albert, Larocca, Alessandra, Usmani, Saad Z, Jagannath, Sundar, Ocio, Enrique M, San Miguel, Jesus, Kher, Uma, Farooqui, Mohammed, Liao, Jason, Marinello, Patricia, and Lonial, Sagar

Published
2019
Full Text
View/download PDF

5. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Author

Lim, Andrew, Grigoriadis, George, Walker, Trish, Nicol, Andrew, LeBlanc, Richard, Reece, Donna, Elemary, Mohamed, Boudreault Pedneault, Jean Samuel, Karlin, Lionel, Facon, Thierry, Attal, Michel, Weisel, Katja, Engelhardt, Monika, Mackensen, Andreas, Quinn, John, Avivi, Irit, Cohen, Amos, Magen-Nativ, Hila, Benyamini, Noam, Cavo, Michele, Larocca, Alessandra, Takezako, Naoki, Suzuki, Kenshi, Kosugi, Hiroshi, Matsumoto, Morio, Iida, Shinsuke, Ishikawa, Takayuki, Kondo, Yukio, Sunami, Kazutaka, Ando, Kiyoshi, Teshima, Takanori, Chou, Takaaki, Iwasaki, Hiromi, Miki, Hirokazu, Matsumura, Itaru, Onishi, Yasushi, Izutsu, Koji, Kizaki, Masahiro, George, Anupkumar, Blacklock, Hillary, Simpson, David, Schjesvold, Fredrik, Waage, Anders, Samoilova, Olga, Nikitin, Evgeniy, Chagorova, Tatiana, McDonald, Andrew, Patel, Moosa, Oriol Rocafiguera, Albert, San Miguel Izquierdo, Jesus, Mateos, Maria, Streetly, Matthew, Forsyth, Peter, Jackson, Graham, Jenkins, Stephen, Rifkin, Robert, Yimer, Habte, McCroskey, Robert, Martincic, Danko, Tarantolo, Stefano, Larson, Sarah, Faroun, Yacoub, Vaughn, Jennifer, Baz, Rachid, Saylors, Gene, Neppalli, Amarendra, Raptis, Anastasios, Fung, Henry, Janosky, Maxwell, Stevens, Don, Coleman, Morton, Costa, Dennis, Cross, Scott, Fanning, Suzanne, Berges, Daniel Farray, Harris, Thomas, Zackon, Ira, Atanackovic, Djordje, Lee, Kelvin, Oliff, Ira, Lee, Wes, Bensinger, William, Lutzky, Jose, Baron, Ari, Hayek, Fadi, Kirschner, Eli, Bharany, Neeraj, Overton, Lindsay, Mannem, Siva, Harroff, Allyson, Jain, Sharad, Roque, Tammy, McIntyre, Kristi, Yasencha, Christopher K, Houck, William, Usmani, Saad Zafar, Oriol, Albert, Rifkin, Robert M, Yimer, Habte Aragaw, McCroskey, Robert Donald, Lim, Andrew Boon Ming, Jagannath, Sundar, Lonial, Sagar, Ghori, Razi Uddin, Farooqui, Mohammed Z H, Marinello, Patricia, and San-Miguel, Jesus

Published
2019
Full Text
View/download PDF

9. Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study

Author

Beyar Katz, Ofrat, primary, Perry, Chava, additional, Grisariu‐Greenzaid, Sigal, additional, Yehudai‐Ofir, Dana, additional, Luttwak, Efrat, additional, Avni, Batia, additional, Zuckerman, Tsila, additional, Sdayoor, Inbal, additional, Stepensky, Polina, additional, Ringelstein‐Harlev, Shimrit, additional, Bar‐On, Yael, additional, Libster, Diana, additional, Sharvit, Liat, additional, Amit, Odelia, additional, Greenbaum, Uri, additional, Gold, Ronit, additional, Herishanu, Yair, additional, Benyamini, Noam, additional, Avivi, Irit, additional, and Ram, Ron, additional

Published
2023
Full Text
View/download PDF

10. Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to anti CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study

Author

Beyar-Katz, Ofrat, primary, Perry, Chava, additional, Bar-On, Yael, additional, Grisariu, Sigal, additional, Yehudai-Ofir, Dana, additional, Luttwak, Efrat, additional, Avni, Batia, additional, Zuckerman, Tsila, additional, Sdayoor, Inbal, additional, Stepensky, Polina, additional, Ringelstein-Harlev, Shimrit, additional, Libster, Diana, additional, Sharvit, Liat, additional, Amit, Odelia, additional, Greenbaum, Uri, additional, Gold, Ronit, additional, Herishanu, Yair, additional, Benyamini, Noam, additional, Avivi, Irit, additional, and Ram, Ron, additional

Published
2022
Full Text
View/download PDF

11. Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study

Author

Beyar Katz, Ofrat, primary, Perry, Chava, additional, Luttwak, Efrat, additional, Sdayoor, Inbal, additional, Bar-On, Yael, additional, Amit, Odelia, additional, Gold, Ronit, additional, Herishanu, Yair, additional, Benyamini, Noam, additional, Grisariu Greenzaid, Sigal, additional, Avni, Batia, additional, Stepensky, Polina, additional, Libster, Diana, additional, Yehudai-Ofir, Dana, additional, Harlev, Shimrit, additional, Sharvit, Liat, additional, Zuckerman, Tsila, additional, Greenbaum, Uri, additional, Avivi, Irit, additional, and Ram, Ron, additional

Published
2022
Full Text
View/download PDF

13. COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge

Author

Bronstein, Yotam, primary, Gat, Roi, additional, Levi, Shai, additional, Cohen, Yael C., additional, Luttwak, Efrat, additional, Benyamini, Noam, additional, Shragai, Tamir, additional, Vitkon, Roy, additional, Neaman, Miriam, additional, Eilaty, Nili, additional, Levi, Mor, additional, Trestman, Svetlana, additional, Perry, Chava, additional, Herishanu, Yair, additional, and Avivi, Irit, additional

Published
2022
Full Text
View/download PDF

16. Characteristics and recognition of early infections in patients treated with commercial anti‐CD19 CAR‐T cells

Author

Beyar‐Katz, Ofrat, primary, Kikozashvili, Nino, additional, Bar On, Yael, additional, Amit, Odelia, additional, Perry, Chava, additional, Avivi, Irit, additional, Gold, Ronit, additional, Herishanu, Yair, additional, Benyamini, Noam, additional, Duek, Adrian, additional, Ben‐Ami, Ronen, additional, Shasha, David, additional, and Ram, Ron, additional

Published
2021
Full Text
View/download PDF

17. Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma

Author

Avivi, Irit, primary, Balaban, Roi, additional, Shragai, Tamir, additional, Sheffer, Gabi, additional, Morales, Miguel, additional, Aharon, Anat, additional, Lowenton‐Spier, Noa, additional, Trestman, Svetlana, additional, Perry, Chava, additional, Benyamini, Noam, additional, Mittelman, Moshe, additional, Tabib, Yaara, additional, Bar Lev, Tali, additional, Zavaro, Mor, additional, Herishanu, Yair, additional, Luttwak, Efrat, additional, and Cohen, Yael C., additional

Published
2021
Full Text
View/download PDF

18. sj-docx-1-tah-10.1177_20406207211035272 – Supplemental material for Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study

Author

Vitkon, Roy, Netanely, Dan, Levi, Shai, Ziv-Baran, Tomer, Ben-Yzak, Ronit, Katz, Ben-Zion, Benyamini, Noam, Trestman, Svetlana, Mittelman, Moshe, Cohen, Yael, and Avivi, Irit

Subjects
FOS: Clinical medicine, Cardiology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tah-10.1177_20406207211035272 for Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study by Roy Vitkon, Dan Netanely, Shai Levi, Tomer Ziv-Baran, Ronit Ben-Yzak, Ben-Zion Katz, Noam Benyamini, Svetlana Trestman, Moshe Mittelman, Yael Cohen and Irit Avivi in Therapeutic Advances in Hematology

Published
2021
Full Text
View/download PDF

22. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

Author

Mateos, Maria-Victoria, Blacklock, Hilary, Schjesvold, Fredrik, Oriol, Albert, Simpson, David, George, Anupkumar, Goldschmidt, Hartmut, Larocca, Alessandra, Chanan-Khan, Asher, Sherbenou, Daniel, Avivi, Irit, Benyamini, Noam, Iida, Shinsuke, Matsumoto, Morio, Suzuki, Kenshi, Ribrag, Vincent, Usmani, Saad Z, Jagannath, Sundar, Ocio, Enrique M, Rodriguez-Otero, Paula, San Miguel, Jesus, Kher, Uma, Farooqui, Mohammed, Liao, Jason, Marinello, Patricia, Lonial, Sagar, KEYNOTE-183 Investigators, Nicol A, Grigoriadis G, Catalano J, LeBlanc R, Elemary M, Bahlis N, Facon T, Karlin L, Ribrag V, Attal M, Goldschmidt H, Engelhardt M, Weisel K, Mackensen A, Nagler A, Ben Yehuda D, Avivi I, Benyamini N, Magen-Nativ H, Palumbo A, Cavo M, Tobinai K, Iida S, Chou T, Suzuki K, Kosugi H, Taniwaki M, Sunami K, Matsumoto M, Ando K, Ganly P, Blacklock H, Simpson D, George A, Schjesvold F, Gjertsen B, Lahuerta J, Blade J, Oriol Rocafiguera A, Mateos M, Rodriguez-Otero P, Larson S, Atanackovic D, Devarakonda S, Bitran J, Zonder J, Morganstein N, Hay M, Chanan-Khan A, Saylors G, Kio E, Oliff I, Kirkel D, Shtivelband M, Yuen C, Yee A, Shah J, Htut M, Raza S, Chhabra S, Stiff P, Hari P, Bank B, Malek E, Gasparetto C, Faroun Y, Sherbenou D, Kreisle W, Singhal S, Rosenblatt J, Usmani S, Lee W, Safah H, Lutzky J, Suh J, Pan D, Baron A, Manges R, Steis R, Oliveira M, Moreb J, Callander N, Anz B, Raptis A, Stampleman L, Melear J, Boyd T, Garbo L, Klein L, Shao S, Lyons R, McIntyre K, Tarantolo S, Yasenchak C, Yimer H., Mateos, Maria-Victoria, Blacklock, Hilary, Schjesvold, Fredrik, Oriol, Albert, Simpson, David, George, Anupkumar, Goldschmidt, Hartmut, Larocca, Alessandra, Chanan-Khan, Asher, Sherbenou, Daniel, Avivi, Irit, Benyamini, Noam, Iida, Shinsuke, Matsumoto, Morio, Suzuki, Kenshi, Ribrag, Vincent, Usmani, Saad Z, Jagannath, Sundar, Ocio, Enrique M, Rodriguez-Otero, Paula, San Miguel, Jesu, Kher, Uma, Farooqui, Mohammed, Liao, Jason, Marinello, Patricia, Lonial, Sagar, KEYNOTE-183 Investigator, and Nicol A, Grigoriadis G, Catalano J, LeBlanc R, Elemary M, Bahlis N, Facon T, Karlin L, Ribrag V, Attal M, Goldschmidt H, Engelhardt M, Weisel K, Mackensen A, Nagler A, Ben Yehuda D, Avivi I, Benyamini N, Magen-Nativ H, Palumbo A, Cavo M, Tobinai K, Iida S, Chou T, Suzuki K, Kosugi H, Taniwaki M, Sunami K, Matsumoto M, Ando K, Ganly P, Blacklock H, Simpson D, George A, Schjesvold F, Gjertsen B, Lahuerta J, Blade J, Oriol Rocafiguera A, Mateos M, Rodriguez-Otero P, Larson S, Atanackovic D, Devarakonda S, Bitran J, Zonder J, Morganstein N, Hay M, Chanan-Khan A, Saylors G, Kio E, Oliff I, Kirkel D, Shtivelband M, Yuen C, Yee A, Shah J, Htut M, Raza S, Chhabra S, Stiff P, Hari P, Bank B, Malek E, Gasparetto C, Faroun Y, Sherbenou D, Kreisle W, Singhal S, Rosenblatt J, Usmani S, Lee W, Safah H, Lutzky J, Suh J, Pan D, Baron A, Manges R, Steis R, Oliveira M, Moreb J, Callander N, Anz B, Raptis A, Stampleman L, Melear J, Boyd T, Garbo L, Klein L, Shao S, Lyons R, McIntyre K, Tarantolo S, Yasenchak C, Yimer H.

Subjects
Male, medicine.medical_specialty, Pembrolizumab, Antibodies, Monoclonal, Humanized, Dexamethasone, Drug Administration Schedule, 03 medical and health sciences, Pembrolizumab, pomalidomide, dexamethasone, KEYNOTE-183, 0302 clinical medicine, Recurrence, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Progression-free survival, Survival rate, Multiple myeloma, Aged, Proportional Hazards Models, Lenalidomide, Aged, 80 and over, Performance status, business.industry, Hematology, medicine.disease, Pomalidomide, Interim analysis, Progression-Free Survival, Thalidomide, Survival Rate, Myocarditis, Editorial Commentary, Treatment Outcome, Stevens-Johnson Syndrome, 030220 oncology & carcinogenesis, Female, Multiple Myeloma, business, 030215 immunology, medicine.drug
Abstract

Summary Background Pomalidomide and dexamethasone is a standard of care for patients with multiple myeloma in whom bortezomib and lenalidomide treatment has failed. KEYNOTE-183 assessed efficacy and safety of pomalidomide and dexamethasone with or without pembrolizumab in patients with relapsed or refractory multiple myeloma. Here, we present the findings of an unplanned, ad-hoc interim analysis at the request of the US Food and Drug Administration (FDA). Methods KEYNOTE-183 was a randomised, open-label, phase 3 trial done at 97 medical centres across 11 countries (Australia, Canada, France, Germany, Israel, Italy, Japan, New Zealand, Norway, Spain, and USA). Patients aged at least 18 years with multiple myeloma, an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, previously treated with at least two lines of therapy (excluding pomalidomide) and refractory to the last line were randomly assigned 1:1 to the pembrolizumab plus pomalidomide and dexamethasone group or the pomalidomide and dexamethasone group via an interactive voice response or integrated web response system. Patients received oral pomalidomide 4 mg daily on days 1–21 and oral low-dose dexamethasone 40 mg on days 1, 8, 15, and 22 in 28-day cycles, with or without intravenous pembrolizumab 200 mg every 3 weeks. The dual primary endpoints were progression-free survival and overall survival. Efficacy was assessed in all randomly assigned patients and safety was assessed in patients who received at least one dose of study treatment. The trial is registered at ClinicalTrials.gov , number NCT02576977 , and it is closed for accrual. Findings Between Jan 18, 2016, and June 7, 2017, 249 patients were randomly assigned to either the pembrolizumab plus pomalidomide and dexamethasone group (n=125) or the pomalidomide and dexamethasone group (n=124). On July 3, 2017, the FDA established that risks associated with the triple combination outweighed benefits and halted the study. Median follow-up was 8·1 months (IQR 4·5–10·9). Median progression-free survival was 5·6 months (95% CI 3·7–7·5) in the pembrolizumab plus pomalidomide and dexamethasone group versus 8·4 months (5·9–not reached) in the pomalidomide and dexamethasone group; progression-free survival estimates at 6 months were 48% (95% CI 37–58) versus 60% (49–69) at 6 months (hazard ratio [HR] 1·53; 95% CI 1·05–2·22; p=0·98). Median overall survival was not reached (95% CI 12·9–not reached) versus 15·2 months (12·7–not reached; HR 1·61; 95% CI 0·91–2·85; p=0·95); overall survival estimates at 6 months were 82% (95% CI 74–88) versus 90% (82–95). Serious adverse events occurred in 75 (63%) of 120 patients in the pembrolizumab plus pomalidomide and dexamethasone group versus 56 (46%) of 121 patients in the pomalidomide and dexamethasone group. Four (3%) treatment-related deaths occurred in the pembrolizumab plus pomalidomide and dexamethasone group (one each of unknown cause, neutropenic sepsis, myocarditis, and Stevens–Johnson syndrome); myocarditis and Stevens-Johnson syndrome were considered related to pembrolizumab. No treatment-related deaths were reported in the pomalidomide and dexamethasone group. Interpretation The results from this unplanned, FDA-requested, interim analysis showed that the benefit–risk profile of pembrolizumab plus pomalidomide and dexamethasone is unfavourable for patients with relapsed or refractory multiple myeloma. Funding Merck Sharp & Dohme, a subsidiary of Merck & Co (Kenilworth, NJ, USA).

Published
2019

23. Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study

Author

Vitkon, Roy, primary, Netanely, Dan, additional, Levi, Shai, additional, Ziv-Baran, Tomer, additional, Ben-Yzak, Ronit, additional, Katz, Ben-Zion, additional, Benyamini, Noam, additional, Trestman, Svetlana, additional, Mittelman, Moshe, additional, Cohen, Yael, additional, and Avivi, Irit, additional

Published
2021
Full Text
View/download PDF

25. Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with nonabsorbable oral antibiotic treatment: A prospective controlled trial

Author

Oren, Ilana, Sprecher, Hannah, Finkelstein, Renato, Hadad, Salim, Neuberger, Ami, Hussein, Keatam, Raz-Pasteur, Ayelet, Lavi, Noa, Saad, Elias, Henig, Israel, Horowitz, Netanel, Avivi, Irit, Benyamini, Noam, Fineman, Riva, Ofran, Yishai, Haddad, Nuhad, Rowe, Jacob M., and Zuckerman, Tsila

Published
2013
Full Text
View/download PDF

26. Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study

Author

Luttwak, Efrat, primary, Gatt, Moshe E., additional, Lebel, Eyal, additional, Lavi, Noa, additional, Tadmor, Tamar, additional, Natalia, Kreiniz, additional, Benyamini, Noam, additional, Horowitz, Netanel, additional, Geva, Mika, additional, Suriu, Celia, additional, Avivi, Irit, additional, Trestman, Svetlana, additional, Mittelman, Moshe, additional, Rouvio, Ory, additional, and Cohen, Yael C., additional

Published
2020
Full Text
View/download PDF

28. Characteristics and recognition of early infections in patients treated with commercial anti‐CD19 CAR‐T cells.

Author

Beyar‐Katz, Ofrat, Kikozashvili, Nino, Bar On, Yael, Amit, Odelia, Perry, Chava, Avivi, Irit, Gold, Ronit, Herishanu, Yair, Benyamini, Noam, Duek, Adrian, Ben‐Ami, Ronen, Shasha, David, and Ram, Ron

Subjects
DIFFUSE large B-cell lymphomas, INFECTION, CYTOKINE release syndrome, BACTERIAL diseases, CHIMERIC antigen receptors, OLDER patients
Abstract

The characteristics of infections following chimeric antigen receptor T (CAR‐T) cells targeting CD19 in real‐word population are obscure. We analyzed infections' characteristics in the first month among consecutive patients with diffuse large B‐cell lymphoma (DLBCL) (n = 60, median age, 69.3 years), treated with commercial CAR‐T cells. ECOG performance status (PS) was 2‐3 in most patients (58%). Infections were observed in 45% of patients (16, 27%, bacterial infections, and 14, 23%, viral infections). Bacterial infection included clinically documented infection in 7 (Pneumonia, n = 5; periodontal infection, n = 1; and cellulitis, n = 1) and microbiology documented infection (MDI) in 9 patients (Gram‐negative rod, n = 5; Gram‐positive cocci, n = 3, bacteremia; polymicrobial, n = 1). The most common viral infection was cytomegalovirus (CMV) reactivation (n = 10, 17%) leading to initiation of anti‐CMV treatment in 6 (60%) among these patients. None had CMV disease. In univariate analysis, immune effector cell‐associated neurotoxicity syndrome (ICANS) was associated with higher incidence of bacterial infection (OR=4.5, P =.018), while there was a trend for lower incidence of bacterial infections in patients with chemosensitive disease to bridging therapy (OR=0.375, P =.074). Age or PS was not associated with increased risk of bacterial infection. Increase in C‐reactive protein (CRP) prior to fever onset was associated with microbiologically documented infections. We conclude that infections are common in the first month following CAR‐T‐cell administration, however, were not increased in elderly patients or those presenting with poorer PS. Increase in CRP prior to fever onset could support infection over cytokine release syndrome. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

29. Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience

Author

Segman, Yafit, primary, Ribakovsky, Elena, additional, Avigdor, Abraham, additional, Goldhecht, Yair, additional, Vainstein, Vladimir, additional, Goldschmidt, Neta, additional, Harlev, Shimrit, additional, Horwitz, Netanel, additional, Gutwein, Odit, additional, Gurion, Ronit, additional, Itchaki, Gilad, additional, Abadi, Uri, additional, Nemets, Anatoly, additional, Sofer, Orit, additional, Zektser, Miri, additional, Tadmor, Tamar, additional, Dally, Nagib, additional, Filanovsky, Kalman, additional, Leiba, Merav, additional, Sarid, Nadav, additional, Benyamini, Noam, additional, Herishanu, Yair, additional, Ram, Ron, additional, Perry, Chava, additional, and Avivi, Irit, additional

Published
2020
Full Text
View/download PDF

30. Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Author

Segman, Yafit, primary, Ribakovsky, Elena, additional, Avigdor, Abraham, additional, Vainstein, Vladimir, additional, Goldschmidt, Neta, additional, Harlev, Shimrit Ringelstein, additional, Gutwein, Odit, additional, Abadi, Uri, additional, Nemets, Anatoly, additional, Sofer, Orit, additional, Dally, Najib, additional, Filanovsky, Kalman, additional, Leiba, Merav, additional, Sarid, Nadav, additional, Benyamini, Noam, additional, Herishanu, Yair, additional, Ram, Ron, additional, Perry, Chava, additional, and Avivi, Irit, additional

Published
2019
Full Text
View/download PDF

31. Outcomes of Post-Induction Bortezomib Therapy in Patients with Newly diagnosed Multiple Myeloma: A Multi-Center Retrospective Observational Study

Author

Luttwak, Efrat, primary, Gatt, Moshe, additional, Lavi, Noa, additional, Tadmor, Tamar, additional, Kreiniz, Natalia, additional, Benyamini, Noam, additional, Horowitz, Netanel, additional, Suriu, Celia, additional, Avivi, Irit, additional, Trestman, Svetlana, additional, Mittelman, Moshe, additional, Ram, Ron, additional, Rouvio, Ory, additional, and Cohen, Yael, additional

Published
2019
Full Text
View/download PDF

33. ENESTop 192-Weeks Results: Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib

Author

Mahon, Francois-Xavier, primary, Boquimpani, Carla, additional, Takahashi, Naoto, additional, Benyamini, Noam, additional, Clementino, Nelma Cristina D., additional, Shuvaev, Vasily, additional, Lipton, Jeffrey H., additional, Turkina, Anna G., additional, De Paz Arias, Raquel, additional, Moiraghi, Beatriz, additional, Nicolini, Franck E., additional, Dengler, Jolanta, additional, Sacha, Tomasz, additional, Kim, Dong-Wook, additional, Fellague-Chebra, Rafik, additional, Tiwari, Ranjan, additional, Bouard, Catherine, additional, and Hughes, Timothy P., additional

Published
2019
Full Text
View/download PDF

34. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Author

Usmani, Saad Zafar, primary, Schjesvold, Fredrik, additional, Oriol, Albert, additional, Karlin, Lionel, additional, Cavo, Michele, additional, Rifkin, Robert M, additional, Yimer, Habte Aragaw, additional, LeBlanc, Richard, additional, Takezako, Naoki, additional, McCroskey, Robert Donald, additional, Lim, Andrew Boon Ming, additional, Suzuki, Kenshi, additional, Kosugi, Hiroshi, additional, Grigoriadis, George, additional, Avivi, Irit, additional, Facon, Thierry, additional, Jagannath, Sundar, additional, Lonial, Sagar, additional, Ghori, Razi Uddin, additional, Farooqui, Mohammed Z H, additional, Marinello, Patricia, additional, San-Miguel, Jesus, additional, Lim, Andrew, additional, Walker, Trish, additional, Nicol, Andrew, additional, Reece, Donna, additional, Elemary, Mohamed, additional, Boudreault Pedneault, Jean Samuel, additional, Attal, Michel, additional, Weisel, Katja, additional, Engelhardt, Monika, additional, Mackensen, Andreas, additional, Quinn, John, additional, Cohen, Amos, additional, Magen-Nativ, Hila, additional, Benyamini, Noam, additional, Larocca, Alessandra, additional, Matsumoto, Morio, additional, Iida, Shinsuke, additional, Ishikawa, Takayuki, additional, Kondo, Yukio, additional, Sunami, Kazutaka, additional, Ando, Kiyoshi, additional, Teshima, Takanori, additional, Chou, Takaaki, additional, Iwasaki, Hiromi, additional, Miki, Hirokazu, additional, Matsumura, Itaru, additional, Onishi, Yasushi, additional, Izutsu, Koji, additional, Kizaki, Masahiro, additional, George, Anupkumar, additional, Blacklock, Hillary, additional, Simpson, David, additional, Waage, Anders, additional, Samoilova, Olga, additional, Nikitin, Evgeniy, additional, Chagorova, Tatiana, additional, McDonald, Andrew, additional, Patel, Moosa, additional, Oriol Rocafiguera, Albert, additional, San Miguel Izquierdo, Jesus, additional, Mateos, Maria, additional, Streetly, Matthew, additional, Forsyth, Peter, additional, Jackson, Graham, additional, Jenkins, Stephen, additional, Rifkin, Robert, additional, Yimer, Habte, additional, McCroskey, Robert, additional, Martincic, Danko, additional, Tarantolo, Stefano, additional, Larson, Sarah, additional, Faroun, Yacoub, additional, Vaughn, Jennifer, additional, Baz, Rachid, additional, Saylors, Gene, additional, Neppalli, Amarendra, additional, Raptis, Anastasios, additional, Fung, Henry, additional, Janosky, Maxwell, additional, Stevens, Don, additional, Coleman, Morton, additional, Costa, Dennis, additional, Cross, Scott, additional, Fanning, Suzanne, additional, Berges, Daniel Farray, additional, Harris, Thomas, additional, Zackon, Ira, additional, Atanackovic, Djordje, additional, Lee, Kelvin, additional, Oliff, Ira, additional, Lee, Wes, additional, Bensinger, William, additional, Lutzky, Jose, additional, Baron, Ari, additional, Hayek, Fadi, additional, Kirschner, Eli, additional, Bharany, Neeraj, additional, Overton, Lindsay, additional, Mannem, Siva, additional, Harroff, Allyson, additional, Jain, Sharad, additional, Roque, Tammy, additional, McIntyre, Kristi, additional, Yasencha, Christopher K, additional, and Houck, William, additional

Published
2019
Full Text
View/download PDF

35. ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).

Author

Hughes, Timothy P., primary, Boquimpani, Carla, additional, Takahashi, Naoto, additional, Benyamini, Noam, additional, Clementino, Nelma Cristina D., additional, Shuvaev, Vasily, additional, Lipton, Jeffrey Howard, additional, Turkina, Anna G., additional, De Paz Arias, Raquel, additional, Moiraghi, Beatriz, additional, Nicolini, Franck E., additional, Dengler, Jolanta, additional, Sacha, Tomasz, additional, Kim, Dong-Wook, additional, Fellague-Chebra, Rafik, additional, Acharya, Sandip, additional, Bouard, Catherine, additional, and Mahon, Francois-Xavier, additional

Published
2019
Full Text
View/download PDF

36. Depletion of B cells rejuvenates the peripheral B‐cell compartment but is insufficient to restore immune competence in aging

Author

Avivi, Irit, primary, Zisman‐Rozen, Simona, additional, Naor, Shulamit, additional, Dai, Isabelle, additional, Benhamou, David, additional, Shahaf, Gitit, additional, Tabibian‐Keissar, Hilla, additional, Rosenthal, Noemie, additional, Rakovsky, Aviya, additional, Hanna, Ammuri, additional, Shechter, Arik, additional, Peled, Eli, additional, Benyamini, Noam, additional, Dmitrukha, Ekaterina, additional, Barshack, Iris, additional, Mehr, Ramit, additional, and Melamed, Doron, additional

Published
2019
Full Text
View/download PDF

37. Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16)

Author

Duek, Adrian, primary, Trakhtenbrot, Luba, additional, Amariglio, Ninette, additional, Benyamini, Noam, additional, Zilbershats, Itay, additional, Ganzel, Chezi, additional, Shevetz, Olga, additional, Leiba, Ronit, additional, Rozic, Gabriela, additional, Nagler, Arnon, additional, and Leiba, Merav, additional

Published
2019
Full Text
View/download PDF

38. Characteristics and Outcome of Multiple Myeloma Patients Presenting with Anemia Only: a Retrospective Multi-Center Study

Author

Shragai, Tamir, primary, Gatt, Moshe E., additional, Shaulov, Adir, additional, Katodritou, Eirini, additional, Triantafyllou, Theodora, additional, Lavi, Noa, additional, Pouli, Anastasia, additional, Sioni, Anastasia, additional, Vaxman, Iuliana, additional, Zektser, Miri, additional, Ganzel, Chezi, additional, Benyamini, Noam, additional, Trestman, Svetlana, additional, ziv Baran, Tomer, additional, Cohen, Yael C, additional, and Avivi, Irit, additional

Published
2018
Full Text
View/download PDF

39. Real-Life Data on the Outcome of Daratumomab-Refractory Myeloma Patients: Multi-Center Experience

Author

Benyamini, Noam, primary, S, Adir, additional, Gatt, Moshe E., additional, Cohen, Yael C, additional, Avivi, Irit, additional, Trestman, Svetlana, additional, Shvetz, Olga, additional, Tadmor, Tamar, additional, Dally, Najib, additional, Chober, Yevgeny, additional, Magen, Hila, additional, Ganzel, Chezi, additional, Jarchowcky Dolberg, Osnat, additional, Suriu, Celia, additional, and Lavi, Noa, additional

Published
2018
Full Text
View/download PDF

40. Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma.

Author

Herishanu, Yair, Levi, Shai, Kamdjou, Talia, Bornstein, Yotam, Ram, Ron, Benyamini, Noam, Varon, David, Avivi, Irit, and Perry, Chava

Subjects
AUTOIMMUNE hemolytic anemia, LYMPHOCYTIC leukemia, CHRONIC leukemia, IDIOPATHIC thrombocytopenic purpura
Abstract

Keywords: obinutuzumab; AIHA; ITP; CLL EN obinutuzumab AIHA ITP CLL e1 e4 4 12/21/20 20210101 NES 210101 Obinutuzumab is a type II, glycoengineered, humanized anti-CD20 monoclonal antibody, with enhanced direct cell death and antibody-dependent cell-mediated cytotoxicity.1 Obinutuzumab is FDA-approved for chronic lymphocytic leukaemia (CLL) in combination with chlorambucil, ibrutinib or venetoclax as a first-line treatment.2-4 Similar to rituximab, obinutuzumab induces B-cell depletion and reduced antibody production, granting it the potential to effectively treat antibody-mediated autoimmune phenomena. We report here a retrospective analysis of eight patients with CLL/small lymphocytic lymphoma (SLL) who were treated with single-agent obinutuzumab for autoimmune haemolytic anaemia (AIHA) or immune thrombocytopenia (ITP), from September 2018 to March 2020. Among our patients, the results achieved with obinutuzumab were especially impressive in a patient with ITP, resistant to multiple therapies, including splenectomy and rituximab, who rapidly responded to obinutuzumab. A prospective randomized trial comparing the efficacy of obinutuzumab and rituximab in the treatment of AIHA/ITP in patients with CLL/SLL, as well as the optimal duration of treatment (e.g. short-term obinutuzumab), is warranted. [Extracted from the article]

Published
2021
Full Text
View/download PDF

43. ENESTop 144-Week Update: Long-Term Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib

Author

Hughes, Timothy P., primary, Boquimpani, Carla, additional, Takahashi, Naoto, additional, Benyamini, Noam, additional, Clementino, Nelma Cristina D., additional, Shuvaev, Vasily, additional, Merchant, Akil, additional, Lipton, Jeffrey H., additional, Turkina, Anna G., additional, De Paz Arias, Raquel, additional, Moiraghi, Beatriz, additional, Nicolini, Franck E., additional, Dengler, Jolanta, additional, Sacha, Tomasz, additional, Kim, Dong-Wook, additional, Fellague-Chebra, Rafik, additional, Acharya, Sandip, additional, Chaturvedi, Shalini, additional, Bouard, Catherine, additional, and Mahon, François-Xavier, additional

Published
2018
Full Text
View/download PDF

44. Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results.

Author

Mahon, François-Xavier, primary, Boquimpani, Carla, additional, Takahashi, Naoto, additional, Benyamini, Noam, additional, Clementino, Nelma Cristina D., additional, Shuvaev, Vasily, additional, Merchant, Akil, additional, Lipton, Jeffrey H., additional, Turkina, Anna G., additional, De Paz Arias, Raquel, additional, Moiraghi, Beatriz, additional, Nicolini, Franck E., additional, Dengler, Jolanta, additional, Sacha, Tomasz, additional, Kim, Dong-Wook, additional, Fellague-Chebra, Rafik, additional, Acharya, Sandip, additional, Chaturvedi, Shalini, additional, Bouard, Catherine, additional, and Hughes, Timothy P., additional

Published
2018
Full Text
View/download PDF

45. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase

Author

Mahon, François-Xavier, primary, Boquimpani, Carla, additional, Kim, Dong-Wook, additional, Benyamini, Noam, additional, Clementino, Nelma Cristina D., additional, Shuvaev, Vasily, additional, Ailawadhi, Sikander, additional, Lipton, Jeffrey Howard, additional, Turkina, Anna G., additional, De Paz, Raquel, additional, Moiraghi, Beatriz, additional, Nicolini, Franck E., additional, Dengler, Jolanta, additional, Sacha, Tomasz, additional, Takahashi, Naoto, additional, Fellague-Chebra, Rafik, additional, Acharya, Sandip, additional, Wong, Stephane, additional, Jin, Yu, additional, and Hughes, Timothy P., additional

Published
2018
Full Text
View/download PDF

50. Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop

Author

Hughes, Timothy P., primary, Boquimpani, Carla Maria, additional, Takahashi, Naoto, additional, Benyamini, Noam, additional, Clementino, Nelma Cristina D, additional, Shuvaev, Vasily, additional, Ailawadhi, Sikander, additional, Lipton, Jeffrey H., additional, Turkina, Anna G, additional, Moiraghi, Elena Beatriz, additional, Nicolini, Franck E., additional, Dengler, Jolanta, additional, Sacha, Tomasz, additional, Kim, Dong-Wook, additional, Fellague-Chebra, Rafik, additional, Acharya, Sandip, additional, Krunic, Nancy, additional, Jin, Yu, additional, and Mahon, François-Xavier, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results